For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
Dear Colleagues:
Across the country, people, patients and health care providers have been directly impacted by preparations and managing the effects of the COVID pandemic. We have all worked to implement measures to reduce risk of infection even as we have tried to maintain the best care for patients with cancer.
For CCTG, we have defined the following priorities
The CCTG BR31 (NCT02273375) trial, A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer has been closed to accrual to the main study.
The purpose of this study was to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
CCTG and its scope of research has been deemed an essential service by Queen’s University and we continue to be operational for our sites and trial patients. Given the critical nature of our research, we continue to monitor our activities and how trial adjustments can be made to ensure that patients can be managed on protocols.
The CCTG Operations and Statistics Centre has successfully completed the transition to a remote work environment with a small number of support staff in the offices.
As the COVID-19 situation continues to evolve, CCTG is closely monitoring the situation in consultation with our network of investigators and trial staff. The CCTG Operations and Statistical Centre remains operational and has full capabilities to support trial develop and oversight of the current portfolio.For the safety of our community we have completed a transition to remote work for our staff.
CCTG has continued to monitor the developments pertaining to the coronavirus (COVID-19).
CCTG has continued to monitor the developments pertaining to the coronavirus (COVID-19). After careful consideration and evaluation of available information at this time, and out of an abundance of caution for the entire network, the CCTG Annual Spring Meeting for 2020 is cancelled.
CCTG Network Members,
CCTG is actively monitoring the continuing developments pertaining to the coronavirus (COVID-19) . This includes reviewing reliable sources of information nationally and internationally as well as tracking travel restrictions. We are evaluating risks to patient safety, trial conduct and integrity, as well as critical meetings and engagement activities across the network. Safety and security are our top priorities as we review the situation.
The purpose of this study was to find the highest dose of durvalumab or of durvalumab with tremelimumab that can be tolerated without causing very severe side effects when receiving standard chemotherapy and to see what effects the study drugs has on this type of cancer.
